Melbourne-based scientists have, for the first time, discovered how to “switch off” a molecule which is one of the top culprits behind prostate cancer, and is also linked to lung and kidney cancers.

A research team from Sinai Health and the University of Toronto has identified a way to determine which mothers are more likely to deliver a baby preterm, raising the possibility of developing a universal screening strategy.

In parts of the world where traveling to a clinic for routine blood tests is a financial and logistical challenge, HIV patients increasingly have the option to collect and ship a drop of their blood in paper-based devices that absorb the sample and store it for analysis in far-away labs.

Zwitterions sound like a distant cousin of Twitter (X), but in fact they are a common macromolecule found in human cells. Scientists at the University of Sydney are also now using Zwitterions to create materials that could stop blood clots from forming in medical devices and implants.

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to facilitate the uptake of glucose through tissues and organs, leading to an increase in blood glucose (chronic hyperglycemia). Since skeletal muscle is the tissue that uses the most glucose in response to insulin action, it is the most affected tissue by insulin resistance.

COPENHAGEN, Denmark, Feb. 19, 2025 /PRNewswire/ — CathVision, a medical technology company developing advanced electrophysiology solutions, is proud to announce that it has received CE Mark for its breakthrough product, ECGenius System. This regulatory milestone allows CathVision to market and distribute ECGenius System across the European Economic Area (EEA), bringing state-of-the-art electrophysiology solutions to healthcare providers and patients.

ReviveMed uses AI to gather large-scale data on metabolites — molecules like lipids, cholesterol, and sugar — to match patients with therapeutics.